Klorfeson

Quick links to important sections

Klorfeson

Method of action: Ophthalmologicals

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Klorfeson

Property Description
Active Ingredients Chloramphenicol, Prednisolone Acetate
Form Solution (e.g., Otic or Ophthalmic drops)
Pharmacological Class Combination Antibiotic and Corticosteroid
Common Type Dual-Action Topical Preparation
Origin Synthetic

Klorfeson is a sophisticated combination medication designed for topical administration, pairing the broad-spectrum antibiotic Chloramphenicol with the potent anti-inflammatory corticosteroid Prednisolone Acetate. This dual-action approach is crucial for managing localized conditions, often involving the ear or eye, where both bacterial infection and significant inflammation contribute to patient discomfort. It is primarily classified as an Amphenicol-class Antibacterial and a Glucocorticoid. This specific combination is widely clinically recognized for its efficacy in situations demanding both infection control and inflammation reduction.


Composition and Form: What Active Ingredients Does Klorfeson Contain?

Klorfeson is typically formulated as an otic solution (ear drops) or a sterile ophthalmic preparation, containing synthetic active compounds suitable for the topical route of administration. The core of the product includes Chloramphenicol, which works to control bacterial growth, and Prednisolone Acetate, which acts to suppress the immune response. Further components often include Benzocaine for localized pain relief and Glacial Acetic Acid, which helps maintain an inhibitory environment against pathogens. Several similar formulations exist under brand names such as Perfocyn and Ossilex AC, all sharing the core dual composition and topical delivery system.


Dual-Action Purpose: What is Klorfeson's General Benefit?

The primary benefit of Klorfeson is its ability to deliver synchronized infection control and rapid symptomatic relief through its complementary active components. The inclusion of a corticosteroid provides immediate anti-inflammatory benefits, which is a key advantage. This fact means the medicine quickly helps reduce the swelling and redness caused by the inflammation. Furthermore, the presence of Chloramphenicol ensures the treatment is also managing the underlying microbial cause of the issue. This confirmed property means the medicine works against the bacteria causing the problem. This strategic combination allows the medicine to resolve the infection while concurrently providing relief from its most acute symptoms, making it a common choice in scenarios such as acute bacterial otitis externa.

Regulatory References

  1. Chloramphenicol Drug Information (MedlinePlus)

What side effects are possible with Klorfeson?

Possible Side Effects and Safety Information

The safety profile of Klorfeson, which combines the antibiotic Chloramphenicol and the corticosteroid Prednisolone Acetate, is defined by regulatory documents based on localized reactions and the potential for systemic or structural effects. Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOCs).


Documented Adverse Reactions

The most frequently reported adverse reactions upon application are local in nature, often classified as Common or Uncommon. These include transient burning, stinging, irritation, and pruritus (itching) at the application site. Other dermatological effects, such as contact dermatitis, may also be reported.

Serious Safety Constraints

The regulatory profile highlights several serious, though often rare, safety constraints:

  • Ocular Structure: For ophthalmic preparations, prolonged use is specifically associated with the risk of elevated Intraocular Pressure (IOP), which may lead to glaucoma, and the formation of posterior subcapsular cataracts.
  • Systemic Risk: The chloramphenicol component carries a severe, rare risk of Aplastic Anaemia and Bone Marrow Hypoplasia, a non-dose-related constraint that is addressed even with topical use.
  • Endocrine Risk: Potential for HPA axis suppression (Hypothalamic-Pituitary-Adrenal) or Cushing's syndrome is documented, primarily in cases of extensive or prolonged systemic absorption of the corticosteroid.

Population and Duration Notes

Certain safety considerations are tied to specific populations and the duration of use. The pediatric population is noted as being at increased susceptibility to systemic corticosteroid effects. Serious ocular effects and systemic absorption risks are generally linked to prolonged exposure to the medication, as stated in official labeling. Furthermore, the medicine is contraindicated in the presence of most viral (e.g., Herpes simplex) or fungal infections of the application site, a constraint linked to the action of the corticosteroid component.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information emphasizes that an overdose of Klorfeson (Chloramphenicol) carries the risk of two major, potentially fatal toxicities: irreversible aplastic anemia and Gray Syndrome. This information strictly defines when urgent medical attention must be sought.


Documented Overdose Manifestations

System Affected Manifestations (Signs and Symptoms)
Hematologic Aplastic anemia, hypoplastic anemia, thrombocytopenia (unusual bleeding/bruising).
Systemic/CV Gray Syndrome (ashen gray skin color, vomiting, abdominal distension, severe hypotension, and cardiorespiratory failure).

Emergency Action and Regulatory Requirements

The regulatory profile mandates that patients exhibiting any signs of severe systemic toxicity, such as those associated with the Gray Syndrome or symptoms of severe blood disorders, must seek immediate professional medical attention.

Regulatory documents specify that supportive care for overdose may include measures to remove the drug from the body, such as exchange transfusion or charcoal hemoperfusion, and that the medication must be discontinued immediately upon suspicion of toxicity.

Population-Specific Notes

The highest risk for fatal Gray Syndrome is explicitly documented in neonates and premature infants due to their reduced ability to metabolize and excrete the drug.

Therapeutic Uses of Klorfeson

What Klorfeson Treats: Main Uses and Benefits

Klorfeson is commonly used to help with acute localized infections of the external ear canal (otitis externa) and the eye (e.g., bacterial conjunctivitis) that are defined by pronounced inflammation. The preparation is used for managing symptom clusters related to inflammatory or irritative states (such as swelling, redness, and pain) in conditions involving susceptible bacterial growth. This type of formulation is generally considered relevant for conditions where a corticosteroid is needed and a superficial bacterial infection or risk of infection exists. Its core benefit is used for managing both infection and inflammation, which contributes to improved comfort and may assist with supporting the patient during difficult episodes and easing the overall symptom load.


This medication is relevant in conditions characterized by periods of heightened symptoms such as acute bacterial otitis externa, bacterial conjunctivitis, and inflammatory dermatoses complicated by secondary infection. The combined action supports the patient during difficult episodes by easing the symptoms related to inflammatory or irritative states, which may interfere with daily functioning.

“The primary focus is managing discomfort while addressing the underlying microbial cause.”


Quick Fact: Relief for Inflammation
The preparation is applied when symptoms create noticeable physiological strain, and the use of the corticosteroid helps address symptom clusters related to acute swelling and redness.

Eligibility and Restrictions for Use

The eligibility for using Klorfeson (a Chloramphenicol/Prednisolone combination) is strictly defined by government regulatory documents, focusing on patient age, medical history, and specific infection status.

Eligibility Restrictions: Contraindicated Populations

Use is absolutely contraindicated in patients with a known hypersensitivity to Chloramphenicol, Prednisolone, or any component of the formulation. It is also prohibited for individuals with a history of blood dyscrasias or bone marrow suppression.

Contraindicated Group Regulatory Basis
Premature Infants/Neonates Risk of systemic toxicity (Gray Baby Syndrome).
Viral Infections (e.g., Herpes Simplex Keratitis) Risk of masking or worsening infection due to corticosteroid.
Mycobacterial/Fungal Infections Prohibition by official labeling due to corticosteroid component.

Age-Related and Conditional Use

Adults are the primary eligible population when the use is indicated. However, the medicine is not recommended or contraindicated during pregnancy (especially the third trimester) and lactation. Use in children and adolescents is generally restricted to the shortest duration necessary.

  • Organ Function: Caution is required in patients with significantly impaired renal function or hepatic function due to the potential for drug accumulation. The regulatory profile defines eligibility to minimize the systemic risks associated with the active ingredients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Klorfeson largely based on its potential to function as an enzyme inducer in the liver, which accelerates the metabolism of several co-administered medicines, reducing their effectiveness in the body.

Documented Pharmacokinetic Interactions

Interacting Product Category Effect on Co-administered Medicine Practical Implication
Coumarin Anticoagulants (e.g., Warfarin) Decreased anticoagulant effect. Requires close monitoring of Prothrombin Time/INR and dose adjustment of the anticoagulant.
Hormonal Contraceptives (Oral) Reduced contraceptive effectiveness, leading to potential failure. Non-hormonal methods of contraception must be used.
Hydantoins & Barbiturates (e.g., Phenytoin) Reduced therapeutic effect. Requires close monitoring and potential dose adjustment of the co-administered medicine.

Documented Absorption and Pharmacodynamic Interactions

Klorfeson reduces the absorption of Iron preparations, necessitating a separation of administration times to maintain efficacy of the iron supplement. Concurrent use with Sulphonylureas may decrease their effectiveness, requiring monitoring of blood glucose levels. These interactions necessitate consultation with a healthcare professional to manage potential therapeutic failure or unintended consequences resulting from altered drug concentrations.

Mechanism of Action

How Klorfeson Works

Blocking Bacterial Growth through Protein Synthesis Inhibition

The Chloramphenicol component targets the 50S ribosomal subunit in prokaryotic cells. By binding to this essential component, the drug mechanism inhibits protein synthesis (a process known as bacteriostasis), thereby limiting microbial cell growth and replication.


Suppressing Inflammation via Genomic Receptor Activation

Prednisolone Acetate works by activating the intracellular Glucocorticoid Receptor ( GR). This leads to the genomic repression of genes that code for key inflammatory mediators (e.g., cytokines) and indirectly blocks the formation of prostaglandins and leukotrienes. This core mechanism modulates the host's immune reaction and contributes to reduced local vascular permeability and edema formation.


Complementary Dual-Action Mechanism

Klorfeson utilizes a synchronized dual-action mechanism: the antibacterial mechanism results in bacteriostasis, while the anti-inflammatory mechanism involves genomic modulation of the host's immune reaction. This strategic combination coordinates a bacteriostatic effect with the modulation of the host's inflammatory cascade.

Dosage and Administration Information

How to Use Klorfeson — Administration Guidelines

Klorfeson (as a powder for injection) is administered strictly via the intravenous (IV) route. It is generally not given as an intramuscular injection due to unpredictable absorption. Adherence to precise dosing and administration procedures is mandatory for proper use.

Dosing and Administration

The standard adult dose is 50 mg per kilogram of body weight per day (50 mg/kg/day), which is given in divided doses. For severe infections, the dose may be increased, but it must be reduced back to 50 mg/kg/day as soon as clinically possible.

Age Group Standard Daily Dose Dosing Frequency
Adults 50 mg/kg/day Divided doses (e.g., every 6 or 8 hours)
Neonates (under 2 weeks) 25 mg/kg/day 4 divided doses (every 6 hours)

Preparation and Procedure

  1. Reconstitution: The powder for injection must be dissolved in 10 mL of a suitable diluent, such as Sterile Water for Injection.
  2. Administration: The calculated dose must be administered slowly by IV injection over at least 1 to 2 minutes or via intermittent infusion.

Special Instructions: Dosage adjustment is mandatory for patients with impaired liver or kidney function. The duration of therapy is typically 10 to 14 days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Klorfeson

The following overview describes the type and scope of research conducted for Klorfeson's uses, summarizing the existing evidence base without offering treatment recommendations or describing individual results.


Evidence for use in Acute Bacterial Otitis Externa (Ear Infection)

Research has explored the use of combination ear drops in studies related to acute bacterial ear infections, a condition characterized by periods of heightened symptoms. These studies monitored clinical outcome rates and the time interval over which symptoms, such as pain and discharge, were observed to change. Findings describe patterns observed in studies over the acute treatment period, often highlighting changes measured in outcomes reflecting daily functioning. However, comparative evidence is lacking for this specific combination versus some newer alternatives, and long-term effects regarding the maintenance of observed changes are not fully established.


Evidence for use in Bacterial Conjunctivitis and Ocular Inflammation

This preparation was studied for use in research exploring its relationship to bacterial conjunctivitis and associated eye inflammation. The evidence base includes Randomized Controlled Trials that monitored specific endpoints such as microbiological clearance rates and observed outcomes linked to inflammatory or irritative states, like redness and swelling. The research contributes to understanding short-term changes measured in outcomes related to inflammatory and infectious states. What remains uncertain is the therapeutic relevance of the antibiotic component in cases where the cause may be viral agents, a frequent scenario in clinical practice.


Evidence in Specific Patient Groups (Populations Studied) and Uncertainties

Research for acute ear infections primarily applies to adult populations, while studies for conjunctivitis included both adults and relevant pediatric cohorts. The results apply only to the populations studied, and data for certain groups, such as those with specific comorbid conditions, remain insufficient. Comparative evidence is lacking for this specific formulation versus every available dual-action alternative. Furthermore, evidence quality varies across studies, and long-term follow-up remains limited, as primary studies focused mainly on acute phases over defined, short time intervals.

Key Studies & References Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial.

Frequently Asked Questions (FAQ)

Common questions about Klorfeson (FAQ)


Q: Is Klorfeson considered a steroid or a narcotic?

A: Klorfeson contains Prednisolone Acetate, which is classified as a glucocorticoid/corticosteroid. The official documents indicate that this product is not listed as a federally controlled substance or a narcotic drug.


Q: What is the general safety profile of Klorfeson for someone with kidney issues?

A: Official product information notes that impaired kidney function is described as requiring careful professional review. This is because reduced kidney function may necessitate a mandatory adjustment to the dose and could lead to increased exposure to the drug's components.


Q: Are there any major drug classes that should never be mixed with Klorfeson?

A: Regulatory documents list several classes of drugs with significant interaction risks. These include certain anticoagulants, hormonal contraceptives, and certain seizure medications (Hydantoins/Barbiturates). There are also specific warnings against concurrent use with other NSAIDs (such as ibuprofen or aspirin).


Q: Can Klorfeson be given to children?

A: Official regulatory information specifies dosage regimens for neonates (under 2 weeks). Clinical studies have also involved pediatric cohorts for certain approved uses, but data for all pediatric age groups may be limited. The official documents describe that for authorized use in children, a medical professional would rely on the specific dose guidance for that population.


Q: Are there any known interactions between Klorfeson and alcohol?

A: Official warnings describe that concurrent use of the antibiotic component (Chloramphenicol) with alcohol (ethanol) can increase the risk or severity of certain adverse effects. The patient information leaflet contains the specific guidance regarding this potential interaction.


Q: Can I take pain relievers like ibuprofen or aspirin with Klorfeson?

A: Official documents warn against combining the steroid component (Prednisolone) with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen or aspirin. This combination is described as significantly increasing the risk of serious gastrointestinal adverse events, such as stomach ulcers and bleeding.


Q: Can Klorfeson make me feel dizzy or lightheaded?

A: Regulatory documents list side effects such as dizziness, vertigo, or lightheadedness that have been reported in clinical experience. These effects are documented as potential adverse reactions associated with the medication.


Q: What is the risk of developing a serious allergic reaction to Klorfeson?

A: Official documents explicitly warn about the potential for serious hypersensitivity reactions, such as anaphylaxis. The product information describes symptoms such as severe swelling or difficulty breathing as signals that indicate the need for immediate professional medical review.


Q: Is Klorfeson safe to use for women who might become pregnant?

A: Regulatory documents provide a Pregnancy Risk Statement describing the available data on potential risks to the fetus. Official documents state that the decision regarding use during pregnancy involves a medical professional weighing the potential benefit against the potential risk.


Q: Can Klorfeson affect blood pressure readings?

A: Yes, official warnings for the steroid component (Prednisolone) list effects such as fluid retention and potential for elevated blood pressure as documented adverse reactions. Official documents note that patients with pre-existing heart conditions may be identified as requiring careful monitoring.


Q: Is Klorfeson safe for people with known heart problems?

A: Regulatory warnings for the steroid component list conditions such as congestive heart failure and hypertension as conditions that require careful professional consideration or are potential contraindications. This is due to the medication's documented potential to cause fluid retention.


Q: Does Klorfeson affect my ability to drive or operate machinery?

A: Regulatory information notes that side effects such as dizziness, somnolence (drowsiness), and blurred vision are documented. These effects may affect the ability to safely perform skilled tasks, and official labeling describes this potential.


Q: Does Klorfeson impact sleep quality or cause insomnia?

A: Regulatory labels list insomnia (difficulty sleeping), restlessness, or other sleep disturbances as reported side effects of the steroid component.


Q: Is Klorfeson known to cause any changes in mood or behavior?

A: Regulatory documents list behavioral and psychological effects such as mood swings, depression, emotional instability, and nervousness as documented adverse reactions related to the steroid component.


Q: Can Klorfeson cause weight gain or weight loss?

A: Regulatory labels for the steroid component list effects like changes in fluid balance and fat distribution as documented adverse reactions. These metabolic changes may be associated with overall weight changes.


Q: What are the known severe side effects that need immediate attention?

A: The official document clearly highlights signs associated with serious adverse reactions, which are signals for immediate professional medical review. These may include signs of severe infection, bone marrow issues (e.g., aplastic anemia), or severe allergic reactions.


Q: Can I stop taking Klorfeson suddenly?

A: Official documents contain warnings regarding the sudden discontinuation of the steroid component after prolonged use. The labeling describes that gradual dosage reduction (tapering) is often necessary to prevent serious withdrawal effects.


Q: Does taking Klorfeson affect laboratory test results?

A: The official label describes known interferences with specific laboratory tests. These effects may include altered blood glucose levels and changes to readings for certain coagulation or skin tests.


Q: Are there any long-term health risks associated with taking Klorfeson for a long time?

A: Regulatory documents describe that prolonged use of the steroid component is associated with potential risks. These can include bone density loss (osteoporosis), the development of a Cushingoid state, and certain eye conditions like cataracts or glaucoma.


Q: What is the half-life of Klorfeson? (How long does it stay in the system?)

A: Official documents provide detailed pharmacokinetic data, which includes the approximate elimination half-life of the active components (Chloramphenicol and Prednisolone) in the blood. This information indicates the rate at which the drug is cleared from the body.


Q: What happens if I accidentally miss a day of taking Klorfeson?

A: Patient information describes the recommended procedure for a missed dose, which involves consulting a healthcare professional for guidance. This ensures the recommended course of action is taken.


Q: Can older adults (seniors) use Klorfeson safely?

A: Official information typically provides warnings and dosage considerations for the geriatric population due to potential differences in metabolism or pre-existing conditions. The official information describes that the geriatric population may be identified as requiring closer professional monitoring.


Q: How should Klorfeson be stored, like in a refrigerator or at room temperature?

A: The official document provides specific storage conditions (e.g., temperature range, protection from light) required to maintain drug stability and efficacy, and these details are available in the patient information.


Q: What is the process for disposing of expired Klorfeson?

A: Official patient information and guidelines published by regulatory bodies describe methods for the safe disposal of expired or unused medicine. These instructions are designed to prevent accidental exposure and protect the environment.


Q: Is it possible to become dependent on Klorfeson?

A: The official document includes a section on Abuse and Dependence to describe any risk or regulatory classification related to habit-forming potential. Furthermore, regulatory warnings describe the risk of physical dependence on the steroid component.


Q: Does Klorfeson require a prescription, or can I buy it over-the-counter?

A: Regulatory classification dictates whether the medicine is categorized as Prescription Only Medicine (POM) or non-prescription (OTC). This is determined by the composition, strength, and approved uses of the product.

How should Klorfeson be stored and disposed of?

Official Storage and Disposal Requirements for Klorfeson

Authoritative governmental drug labeling for Klorfeson does not currently contain publicly indexed, explicit instructions regarding mandatory storage and disposal protocols. Without specific regulatory statements, key aspects of proper handling remain undefined:

Storage/Disposal Component Official Status
Temperature and Protection Not documented in official sources
Packaging and Stability Not documented in official sources
Disposal Instructions Not documented in official sources

This means that official regulatory documents do not specify required temperature ranges, light or moisture protection, or stability periods for the product. There are also no documented instructions defining whether the medication must be returned to a collection site or discarded as regular household waste. Compliance with the official label is mandatory for patient safety and product integrity.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Klorfeson found in:

A-Z Index: